Drugs / triprilizumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06861192 | Feb 2025 → Mar 2026 overdue | prostate cancer | baotai Liang | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | triprilizumab | “PD-1 monoclonal antibody (triprilizumab, 3mg/kg, intravenous drip)” NCT06861192 ↗ |
| Route | Intravenous | “triprilizumab, 3mg/kg, intravenous drip” NCT06861192 ↗ |